Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProPhase Labs (PRPH) Liabilities from Discontinued Operations: 2023-2024

  • ProPhase Labs' Liabilities from Discontinued Operations rose 100.65% to $5.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.9 million, marking a year-over-year increase of 100.65%. This contributed to the annual value of $5.9 million for FY2024, which is 100.65% up from last year.
  • Per ProPhase Labs' latest filing, its Liabilities from Discontinued Operations stood at $5.9 million for Q4 2024, which was up 100.65% from $2.9 million recorded in Q4 2023.
  • ProPhase Labs' Liabilities from Discontinued Operations' 5-year high stood at $5.9 million during Q4 2024, with a 5-year trough of $2.9 million in Q4 2023.
  • Its 2-year average for Liabilities from Discontinued Operations is $4.4 million, with a median of $4.4 million in 2023.
  • Data for ProPhase Labs' Liabilities from Discontinued Operations shows a peak YoY spiked of 100.65% (in 2024) over the last 5 years.
  • ProPhase Labs' Liabilities from Discontinued Operations (Quarterly) stood at $2.9 million in 2023, then spiked by 100.65% to $5.9 million in 2024.